Samir H. Patel

Dr. Samir H. Patel


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2014 in The Lancet Oncology
Verified
Journal Article
Closed access
SPSamir H. Patel
Samir H. Patel
ZWZhen Wang
Zhen Wang
WWWilliam W Wong
William W Wong
MMMohammad Hassan Murad
Mohammad Hassan Murad
CBCourtney R Buckey
Courtney R Buckey
RFRobert L Foote
Robert L Foote

1 April 2015 in JAMA Otolaryngology–Head & Neck Surgery
Verified
Journal Article
Open access
PDF file
SPSamir H. Patel
Samir H. Patel
RHRichard E. Hayden
Richard E. Hayden
MHMichael L. Hinni
Michael L. Hinni
WWWilliam W. Wong
William W. Wong
RFRobert L. Foote
Robert L. Foote
MHMichele Y. Halyard
Michele Y. Halyard
Angiosarcoma is an aggressive malignant tumor of the vascular endothelial cells. In most cases, its etiology is unknown. However, some factors have been associated with an increased risk for angiosarcoma, including prior radiation exposure, chronic lymphedema (Stewart-Treves syndrome), and exposure to chemicals such as polyvinyl chloride, thorium dioxide, arsenic, and radium. Angiosarcoma can involve any anatomic site, with the skin being the most common. It accounts for approximately 5% of cutaneous soft-tissue sarcomas.1 Cutaneous angiosarcomas are more common in the head and neck region and account for more than 60% of cases.2 The diagnosis of cutaneous angiosarcoma can be challenging because it often presents insidiously as a bruiselike lesion or a purplish papule that may be mistaken for a benign lesion such as hemangioma.

1 December 2018 in Oral Oncology
Verified
Journal Article
Closed access
MGMauricio E. Gamez
Mauricio E. Gamez
RKRyan Kraus
Ryan Kraus
MHMichael L. Hinni
Michael L. Hinni
EMEric J. Moore
Eric J. Moore
DMDaniel J. Ma
Daniel J. Ma
SPSamir H. Patel
Samir H. Patel

9 April 2016 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
KCKelly K. Curtis
Kelly K. Curtis
HRHelen J. Ross
Helen J. Ross
AGAshley L. Garrett
Ashley L. Garrett
TJTheresa A. Jizba
Theresa A. Jizba
APAjay B. Patel
Ajay B. Patel
RFRobert L. Foote
Robert L. Foote
We reviewed outcomes of patients with loco-regionally recurrent (LRR) or new primary (NP) squamous cell carcinoma of the head and neck (SCCHN) treated at our institution with reirradiation (RRT). Patients received definitive RRT (DRRT) or post-operative RRT following salvage surgery (PRRT) from 2003 to 2011. Measured survival outcomes included loco-regional relapse free survival (LRFS) and overall survival (OS). Among 81 patients (PRRT, 42; DRRT, 39), median PRRT and DRRT doses were 60 Gy (12–70 Gy) and 69.6 Gy (48–76.8 Gy). The majority of patients received IMRT-based RRT (n = 77, 95 %). With median follow-up of 78.1 months (95 % CI, 56–96.8 months), 2-year OS was 53 % with PRRT and 48 % with DRRT (p = 0.12); 23 % of patients were alive at last follow-up. LRFS at 2 years was 60 %, and did not differ significantly between PRRT and DRRT groups. A trend toward inferior LRFS was noted among patients receiving chemotherapy with RRT versus RRT alone (p = 0.06). Late serious toxicities were uncommon, including osteoradionecrosis (2 patients) and carotid artery bleeding (1 patient, non-fatal). OS of PRRT- and DRRT-treated patients in this series appears superior to the published literature. We used IMRT for the majority of patients, in contrast to several series and trials previously reported, which may account in part for this difference. Future studies should seek to improve outcomes among patients with LRR/NP SCCHN via alternative therapeutic modalities such as proton radiotherapy and by incorporating novel systemic agents.

29 April 2022 in Seminars in Oncology
Verified
Journal Article
Closed access
RBRs Bhangoo
Rs Bhangoo
TCTw Cheng
Tw Cheng
MPMm Petersen
Mm Petersen
CTCs Thorpe
Cs Thorpe
TDTA DeWees
TA DeWees
WWWw Wong
Ww Wong

1 June 2012 in American Journal of Clinical Oncology
Verified
Journal Article
Closed access
SPSamir H. Patel
Samir H. Patel
JRJared Robbins
Jared Robbins
EGElizabeth M. Gore
Elizabeth M. Gore
JBJeffrey D. Bradley
Jeffrey D. Bradley
LGLaurie E. Gaspar
Laurie E. Gaspar
GVGregory M. Videtic
Gregory M. Videtic
Multiple options for retreatment are available, which include whole-brain radiation therapy, stereotactic radiosurgery, surgery, chemotherapy, and supportive care. Size, number, timing, location, histology, performance status, and extracranial disease status all need to be carefully considered when choosing a treatment modality. There are no randomized trials examining the retreatment of brain metastases. Repeat whole-brain radiation has been examined in a single-institution experience, showing the potential for clinical responses in selected patients. Local control rates as high as 91% using stereotactic radiosurgery for relapses after whole-brain radiation are reported. Surgery can be indicated in progressive and/or hemorrhagic lesions causing mass effect. The role of chemotherapy in the recurrent setting is limited but some agents may have activity on the basis of experiences on a smaller scale. Supportive care continues to be an important option, especially in those with a poor prognosis. Follow-up for brain metastases patients is discussed, examining the modality, frequency of imaging, and imaging options in differentiating treatment effect from recurrence. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every 2 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of the current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.